Cepheid Gets FDA Nod for Antimicrobial Resistance Test | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid said today that it has received clearance from the US Food and Drug Administration to market its Xpert vanA test for the antimicrobial resistance gene most commonly associated with vancomycin-resistant enterococci.

The 45-minute test runs on Cepheid's GeneXpert System, and is the first rapid and accurate test released in the United States for vanA, Cepheid said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.